|
|
426 N. San Gabriel Avenue
Azusa, CA 91702
phone:626) 804-3645
fax:(626) 529-0907
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.medomics.com
|
|
| Research Sector |
Healthcare Services |
|
 |
| Summary Description |
| Sequencing of genome data for personalized medicine |
|
| Management |
| Stan Yakatan, Chairman; Steve Sommer, MD, PhD, President and CMO; Nicolas Nickelmann, PhD, COO; Craig Camp, MBA, CFO; Bill Scaringe, MS, MS, Director of Bioinformatics |
| |
|
|
| |
|
| Keywords |
| massively-parallel sequencing, genome, bioinformatics, mitochondrial diseases |
|
|
|
| Description |
|
MEDomics provides Mutation Expert-based Diagnosis (“MED”) of patients’ genome data to enhance personalized medicine through the employment of bioinformatics, clinical genetics, and mutation. MEDomics is the first fully-certified CLIA lab to focus on next Gen sequencing, which is massively-parallel sequencing accompanied by expert analysis and interpretation sequencing. Interpretation by the Company represents 80% of the information and effort provided to the physician ordering the test, which facilitates a more definitive diagnosis. The Company has a proprietary bioinformatics database focused on mitochondrial medicine. MitoDX is capable of sequencing the mitochondrial genome thousands of times, providing heterosplasmy down to 1%. MitoNucleomeDX analyzes 312 nuclear genes necessary for mitochondrial function, and while reports are typically 7-20 pages, the key data is usually summarized for the physician in the first 3-5 sentences of a report. This later-stage biotechnology company has more than two decades of experience in the DNA diagnostic field and is raising $2-3M for expansion. |
|
| Technology / Differentiation |
| Diagnostic testing at MEDomics is based on NextGen Sequencing (massively-parallel sequencing), accompanied by expert analysis and interpretation of results. The interpretation reflects two decades of DNA diagnostic experience supplemented by intensive review of the literature and knowledge gained at appropriate national and international meetings. Tests within the division range from multi-gene panels for polygenic disorders to complete sequencing of an individual's entire genome. |
|
|
| Strategy |
The competitive advantages that MEDomics encompasses (please find partial list below), outlines why an investment in us may be attractive.
- Major first mover advantages that are difficult to duplicate
- Functioning, integrated, and tested team with an unrivaled track record for bringing novel molecular diagnostics to market
- Enhanced trade secrets and intellectual property pipeline
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members